Mark Roberts

High Impact

Researcher

University of Arkansas for Medical Sciences

faculty

38 h-index 202 pubs 5,813 cited

Research Areas

Metabolism and Genetic Disorders Neurological disorders and treatments Mitochondrial Function and Pathology Pharmacological Effects and Toxicity Studies Health Sciences Research and Education Meta-analysis and systematic reviews Emergency and Acute Care Studies

Links

Research Group

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Mark Roberts, a faculty member at the University of Arkansas for Medical Sciences, leads a research group focused on investigating metabolic and genetic disorders, particularly Pompe disease. His work includes evaluating the safety and efficacy of enzyme replacement therapies for late-onset Pompe disease, as demonstrated by his participation in Phase 3 clinical trials such as COMET and PROPEL. These trials assessed treatments like avalglucosidase alfa, alglucosidase alfa, and cipaglucosidase alfa, often in combination with other agents like miglustat.

Roberts also contributes to broader clinical guidelines and consensus statements within the field of thoracic medicine, including guidelines for pleural disease and statements on the use of fibrinolytics and deoxyribonuclease for pleural empyema. His research extends to forecasting outcomes in mitochondrial diseases, specifically stroke-like episodes. He has co-authored publications with Thomas Andrew Burrow, also at the University of Arkansas for Medical Sciences. Roberts' scholarly contributions are reflected in his h-index of 38 and over 5,800 citations across more than 200 publications.

Metrics

h-index: 38
Publications: 202
Citations: 5,813

Selected Publications

An Indirect Treatment Comparison of Avalglucosidase Alfa versus Cipaglucosidase Alfa Plus Miglustat in Patients with Late-Onset Pompe Disease (2025) DOI
Myo‐Guide: A Machine Learning‐Based Web Application for Neuromuscular Disease Diagnosis With MRI (2025) DOI
Neurophysiology Muscle Disorders—Channelopathies (2024) DOI
Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease (2024) DOI
670P Post-baseline outcomes of the UK Early Access to Medicines Scheme registry for cipaglucosidase alfa plus miglustat in late-onset Pompe disease (2024) DOI
599P The UK Facioscapulohumeral Muscular Dystrophy Patient Registry: a powerful tool to support clinical research and patient voice in the translational research pathway (2024) DOI
Decoding the muscle transcriptome of patients with late-onset Pompe disease reveals markers of disease progression (2024) DOI
Start, switch and stop (triple‐S) criteria for enzyme replacement therapy of late‐onset Pompe disease: European Pompe Consortium recommendation update 2024 (2024) DOI
The class that is hard work for the last period of the day (2024) DOI
The students who hate sitting next to each other (2024) DOI
Headache Characteristic Changes During the Typical Recovery Period After Pediatric Sport-related Concussion (P2-14.001) (2024) DOI
The Evaluation and Management of Concussion to Optimize Safe Recovery (2024) DOI
P028: Switching treatment to cipaglucosidase alfa+miglustat positively affects motor function and quality of life in patients with late-onset Pompe disease (2024) DOI
104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07) (2024) DOI
Switching treatment to cipaglucosidase alfa plus miglustat positively affects motor function and quality of life in patients with late-onset Pompe disease (2024) DOI